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Introduction
Diabetes Mellitus (DM) is a life-long condition characterized by the 
presence of chronic hyperglycemia with impairment in the metabolism 
of carbohydrates, lipids and proteins. It is a multifactorial disease that 
occurs because of various pathophysiological causes and processes. 
DM is a major public health problem since globally, according to the 
latest report from the International Diabetes Federation; 415 million 
people were affected with DM in 2015, with increasing incidence and 
prevalence [1]. DM is mostly diagnosed in adults, but in the last 20 
years, the incidence in the pediatric age group has markedly increased. 
Depending on different populations, variations between incidence rates 
are observed, unlike gender, where the incidence is equally distributed; 
it is more common in developed countries and the risk of occurrence 
increases with obesity, reduced physical activity and age [2,3]. 
DM represents a group of metabolic disorders that can be 
classified by etiology and pathology as type 1 or type 2 DM, gestational 
diabetes and “other specific types” (monogenic diabetes). Type 1 DM 
is a genetic disease characterized by autoimmune pancreatic beta cell 
destruction that leads to loss of insulin production, insulin deficiency 
and hyperglycemia. As the response to the loss of insulin secretion, 
abnormal function of alpha cells appears likewise excessive secretion of 
glucagon. In a healthy organism, glucagon secretion is suppressed by 
hyperglycemia, but in type 1 DM, an elevated glucagon concentration 
aggravates metabolic defects due to insulin deficiency. In response to 
insulin deficiency, uncontrolled lipolysis and elevated levels of free fatty 
acids occur in the plasma [4]. On the other hand, type 2 DM comprises a 
group of genetic diseases with similar symptoms and outcomes, but with 
different genetic backgrounds and pathophysiological processes. The 
dysfunction of beta cells leads to impaired insulin secretion, and as the 
main consequence, insulin resistance develops. Since insulin resistance 
occurs, beta cells increase the production of insulin in order to maintain 
blood glucose level and ensure normal body function. Over years, beta 
cells begin to fail, insulin secretion decreases, and blood glucose levels 
increase. Another defect found in type 2 DM is insulin deficiency due to 
beta cell exhaustion or genetic factors. Individuals with type 2 diabetes 
mostly exhibit intra-abdominal obesity, related to insulin resistance and 
deficiency, hypertension and dyslipidemia [2,5]. 
Complications of Diabetes
The development of diabetic complications could be classified 
according to different mechanisms of their pathophysiology into 
macrovascular, microvascular and neurologic complications. The most 
common cause of death related to the macrovascular complication is 
atherosclerosis of the coronary arteries. Pathophysiology of small and 
large vessel disease include effects on capillaries all over the body and 
effects on mostly involved organs, eyes and kidneys. Adult blindness 
and diabetic nephropathy are the most common consequences of 
diabetic retinopathy. The permeability of vascular and nerve tissues 
and the ability for their glucose intake into cells, without the presence 
of insulin, increases the glucose level in the cells. Disposal mechanisms 
consequently can cause damage to blood vessels and nerves. All 
mentioned complications lead to delayed wound healing in diabetes, 
emerged from impaired processes of complex mechanisms of tissue 
reparation and regeneration [6]. Diabetic neuropathy, described as 
a loss of sensation in feet, leads to the formation of foot ulcers, which 
is currently considered as the leading cause of hospital admissions of 
diabetic patients. Approximately 15% of diabetic patients are affected 
by a diabetic foot ulcer. It is a major health problem since it causes pain, 
suffering and poor life quality [7].
Therapeutic Approaches in Diabetes
Early diagnosis and treatment of DM are crucial in the prevention 
of its possible complications. Different diagnostic tests such as Random 
plasma test, Fasting plasma glucose test, Oral glucose tolerance test, and 
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Abstract
Dipeptidyl Peptidase IV or molecule CD26 (DPP IV/CD26) is a multifunctional protein, identified as a therapeutic 
target for type 2 diabetes, due to its ability to degrade incretins, insulin secretagogues. Delayed wound healing is 
a significant complication in diabetic patients that represents a major socio-economic health problem. It has been 
proposed that DPP IV/CD26 inhibition accelerates healing of chronic diabetic ulcers in those patients, through the 
induction of a histological pattern consistent with enhanced angiogenesis. Studies on mice models of diabetes-
disturbed wound healing also suggested that the inhibition of DPP IV enzymatic activity may improve tissue 
regeneration processes. However, further research is needed to elucidate the role of DPP IV/CD26 in diabetic 
wound healing. The objective of this work was to discuss recent findings on the implications of DPP IV/CD26 in tissue 
regeneration and reparation in diabetic environment.
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others for identification of both types of diabetes are available, but the 
rate of undiagnosed patients is still high. Achieving balanced diabetes 
treatment is the key management strategy for treating patients with both 
type 1 and 2 DM. The first goal of the diabetic treatment is to achieve 
and maintain stable euglycemia and the process starts with a diabetic 
plan of nutrition as well as the administration of oral anti-hyperglycemic 
agents. Personalized insulin therapies in type 1 DM patients last for life. 
In type 2 DM, in response to insulin insufficiency, insulin therapy is also 
needed. Surgical management of diabetes is also available. In type 2 DM, 
circulating levels of glucose and fatty acids contribute to dysfunction of 
beta cells. To restore the deficient beta cells, transplantation of pancreatic 
islets cells, endowed with the capillary network is also a therapeutic option 
[2]. The success of the method is contributed by vascularization factors, 
one of them being vascular endothelial growth factor (VEGF), crucial for 
creating de novo blood vessels. Another important molecule for which it 
has been proven in vivo that expands islet mass by increasing beta cell 
number and induces islet neogenesis is glucagon-like-peptide 1 (GLP-1). 
However, its biological availability is controlled by dipeptidyl peptidase 
IV (DPP IV/CD26), a moonlighting protein with an enzymatic function 
which cleaves active GLP-1. One of the most important implications of 
DPP IV/CD26 inhibitors is indeed therapeutic support of DM, where 
it found its clinical importance, given its capability to contribute to the 
maintenance of glucose homeostasis [8].
Dipeptidyl Peptidase IV/Molecule CD26 (DPP IV/
CD26)
Dipeptidyl peptidase IV (DPP IV/CD26, EC 3.4.14.5), the main 
member of the DPP IV/CD26 family of proteins, is a ubiquitous 
multifunctional transmembrane glycoprotein, present also in a soluble 
form in plasma and other biological fluids, acting as a proteolytic and 
costimulation molecule, and binding protein. It is known that DPP IV/
CD26 cleaves off an N-terminal dipeptide from substrates with Ala or 
Pro in their penultimate position, but it is also known as the marker 
of cell surface T lymphocytes-CD26 and adenosine deaminase. It 
is expressed on the surface of various cell types in almost all tissues, 
including epithelial, endothelial and immune cells [9]. It plays a 
significant role in many physiological as well as pathological processes. 
DPP IV/CD26 was largely investigated since it is involved in the process 
of maintaining glucose homeostasis. Moreover, given the positive effects 
of DPP IV/CD26 inhibition in the mechanisms of chronic diabetic 
foot ulcers healing, as well as other pathologies, growing efforts are 
being made in order to elucidate the role of this molecule in crucial 
molecular pathways. It was shown that DPP IV/CD26 is implicated 
in key processes in wound healing. Its role in the regulation of cell 
adhesion, migration, apoptosis, angiogenesis and extracellular matrix 
degradation was previously confirmed. It was indicated that DPP IV/
CD26 plays a particularly relevant role in tissue regeneration where it 
was found to influence inflammatory processes and impacts the process 
of epithelialization of wounds [6,7,10].
Molecular and Biological Properties of DPP IV/CD26
The relative molecular mass of a human DPP IV/CD26 dimer 
molecule is about 240 000 Da and contains 766 polypeptide residues. 
The transmembrane hydrophobic domain contains 22 amino acids, 
while the N-terminus contains a short intracellular sequence of 6 amino 
acids and a C-terminal catalytic region. The remaining 738 residues are 
located extracellularly and serve as glycosylation sites. The gene coding 
the DPP IV/CD26 protein is located on the long arm of chromosome 
2q24.2 and contains 26 exons [11].
DPP IV/CD26 plays important roles in multiple biological fields 
ranging from immunology, glucose homeostasis, cancer biology, 
inflammation and various chronic diseases. At least five functions of DPP 
IV/CD26 have been shown so far: it has an enzymatic function as a serine 
protease, it acts as a receptor, an adhesion molecule for fibronectin and 
collagen and, as a protein, it is involved in ligand-receptor interactions. 
In the immune system, DPP IV/CD26 serves as a costimulatory surface 
molecule, modulating chemotaxis and influencing T-cell activity [12]. 
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Figure 1: Schematic representation of causal connections between DPP IV/CD26 and its substrates, main molecules involved in angiogenesis and glucose 
homeostasis.
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The presence of the amino acid proline gives unique structural 
features to peptides and many biologically important peptides, such 
as neuropeptides, hormones, cytokines, chemokines. Indeed, proline 
serves as a regulatory element in the process of proteolysis. DPP 
IV/CD26 is one of the members of a small group of proteases that 
recognize and cleave substrates that contain proline (or alanine) on the 
penultimate position in a polypeptide chain. The substrate specificity is 
arranged by the molecular environment of the active site [12,13]. 
Acting as a receptor, DPP IV/CD26 binds to adenosine deaminase 
(ADA). Because of ADA`s role in the development and function of 
lymphoid tissues, ADA deficiency causes defects in immune response 
and hematologic malignancies. The complex of ADA-DPP IV/CD26 
reduces local concentrations of adenosine, while on the surface of 
T cells induces cell proliferation. After the catalytic action of DPP 
IV/CD26 on chemokines, it reduces their chemotactic activity. For 
instance, the colocalization of DPP IV/CD26 with the chemotactic 
receptor CXCR4, which is a receptor for stromal cell-derived factor 
1α (SDF-1α), influences CXCR4-signaling properties for attracting 
endothelial progenitor cells at the inflammatory site. SDF-1α locally 
produced in damaged and inflamed tissues promotes angiogenesis and 
has an important role in diabetes as a protector of stem-cell-derived 
insulin-producing cells from glucotoxicity and as a promotor of beta-
cell survival in mice [14]. 
Patients with type 2 DM show decreased insulin secretion and 
decreased effect of incretin hormones actions. The insulinotropic 
hormone GLP-1 is a DPP IV/CD26 substrate that shows a causal 
connection with wound healing in diabetic patients. DPP IV/CD26 
cleaves the active form of GLP-1 (7-36) to form an inactive form of 
GLP-1 (9-36) thus modifying its biological activity [15]. After the 
processing of GLP-1 by DPP IV/CD26 enzymatic activity, its affinity 
for GLP-1 receptor decreases and effects directly on the production and 
activity of insulin (Figure 1). Active GLP-1 is important as it stimulates 
the excretion of glucose-stimulated insulin, increases the biosynthesis 
of insulin, stimulates the growth and proliferation of beta cells, and 
inhibits the excretion of glucagon [2]. An important role of DPP IV/
CD26 inhibitors on decreasing proteasome activity was found in order 
to preserve angiogenic factors and angiogenesis at the wound site [7].
Biologically Important Molecules Related to DPP IV/
CD26
NPY is a 36-amino acid neuropeptide, involved in the control 
of feeding, blood pressure, and energy homeostasis. It is known that 
NPY binds to 5 types of receptors (subtypes Y1-Y5). The receptor 
with significant properties in the processes of wound healing is the 
Y1 receptor, located on vascular smooth muscle cells, which promotes 
vasoconstriction and proliferation of cells. DPP IV/CD26 changes 
the ability of NPY to bind to its Y1 subtype of receptor and therefore 
terminates the action of NPY at the Y1 receptor, moderating thus the 
regulation of vascular smooth muscle contraction and angiogenesis 
[16]. Furthermore, an important role of NPY was noticed in pancreatic 
beta-cell survival as well as in glucose homeostasis, where NPY has the 
ability to suppress insulin secretion [14].
Substance P is a neuropeptide with important immunoregulatory 
functions that also acts as a potent contractor of smooth muscles. The 
cleavage of substance P by DPP IV/CD26 terminates its function in the 
degranulation of mast cells. A truncated substance P can further be 
cleaved by aminopeptidases, taking part in the degradation pathway in 
the vascular endothelium. Cleaved substance P directly inhibits insulin-
dependent glucose metabolism in rats. Its involvement in diabetic 
corneal wound healing has also been shown [17]. Furthermore, it is 
known that DPP IV/CD26-mediated truncation of substance P could 
modulate the sense of pain in wounds [17,18] (Table 1). 
Among molecules causally connected with DPP IV/CD26, a 
crucial role is played by VEGF, a factor that stimulates angiogenesis 
and neovascularization, the formation of granulation tissue and 
epidermal repair, having, therefore, a major role in wound healing. In 
diabetic patients, chronic non-healing wounds are often present. Low 
levels of active VEGF protein were found in diabetic wounds, which 
consequently leads to insufficient wound vascularization and delay in 
the tissue repair process [19]. 
Hypoxia-inducible factor 1α (HIF-1α) is a transcriptional factor 
responsible for gene transcription, whose protein products mediate 
adaptive responses to hypoxia. Under hypoxic conditions, HIF-1α 
promotes the upregulation of genes responsible for adaption in reduced 
oxygen environment [20]. Hypoxia encourages the release of growth 
factor VEGF, stimulating proliferation and migration of cells. HIF-1α 
regulates the expression of VEGF in the process of wound healing. It was 
shown that the active form of GLP-1 promotes the upregulation of HIF-
1α. GLP-1 binds to its receptor (GLP-1R) situated mainly on pancreatic 
alpha and beta cells and therefore stimulates glucose-dependent insulin 
production. Previous studies evidenced that GLP-1 improves the 
generation of the angiogenic factor VEGF in human pancreatic islet 
environment [21]. Likewise, increased GLP-1 concentrations reduce 
the activation of the proteasome activity induced by oxidative stress [7]. 
In hyperglycemic conditions, HIF-1α is destabilized and its function is 
impaired, leading to delayed wound healing. 
Another important substrate of DPP IV/CD26 involved in wound 
healing is the chemokine interferon-inducible protein 10 (IP-10 or 
CXCL10), which appears in homeostasis/coagulation phase, and 
plays a major role in the recruitment of activated CD4, CD8 and NK 
cells. Induced by infection and inflammation, the upregulation of the 
angiostatic molecule IP-10 causes vessel regression in the modeling 
phase of wound healing. In chronic wounds, the levels of inflammatory 
cytokines as well as IP-10 are increased. IP-10 is highly expressed 
during the granulation phase, but in chronic wounds, such as skin 
wounds in patients with type 2 diabetes, wounds remain static in the 
inflammatory phase and cannot proceed to the granulation stage [22]. 
Physiological System/Process Regulatory Peptide/Chemokine/Hormone
Digestive and Vascular Gastrin releasing peptide (GRP), glucagon-like peptide (GLP)-2, trypsinogen, pro-colipase, eneterostatin, aprotinin, bradykinin
Glucose metabolism and homeostasis GLP-1 (7-37), glucagon, gastric inhibitory polypeptide GIP (1-42)
Endocrine and nervous Pituitary adenylyl cyclase-activating peptide-1 (PACAP-1), vasostatin-1, thyrotropin-α, substance P (SP), neuropeptide Y (NPY), peptide YY (PYY), endomorphins
Immune 
IL-2, IL-1β, RANTES, SDF-1α, SDF-1β, macrophage-derived chemokine (MDC), macrophage inflammatory protein (MIP)-1α 
and 1β, eotaxin, interferon-γ-inducible protein-10 (IP-10), interferon-inducible T-cell alpha chemoattractan (I-TAC), monocyte 
chemotactic protein (MCP)-1, -2 and -3, granulocyte chemotactic protein-2
Growth and healing Insulin-like growth factor 1 (IGF-1), growth hormone releasing factor and hormone (GRFH and GRFR)
Table 1: Identified substrates of DPP IV/CD26 that directly or indirectly regulate various physiological functions [11-13,18].
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DPP IV/CD26 mediates cleaving of IP-10, producing an antagonist 
form of the chemokine thus causing failure of vessel regression and 
tendency to ulceration and dehiscence. DPP IV/CD26 reduces the 
chemotactic ability of IP-10 and leaves the ability of IP-10 to inhibit 
angiogenesis [23].
DPP IV/CD26 Inhibitors in Treatment of Diabetes
DPP IV/CD26 inhibitors are oral hypoglycemic agents used either 
as a monotherapy of type 2 diabetes or in combination with other 
therapeutic agents such as metformin. The first clinical proof-of-
concept study about the role of DPP IV/CD26 inhibitors in glucose-
lowering treatment for type 2 diabetes was reported in the early 2000s 
[24]. It was first shown that the inhibition of DPP IV/CD26 elevates 
levels of circulating GLP-1, decreases glucagon concentrations and 
consequently lowers blood glucose levels. The research was based on 
known data about GLP-1 peptide as a potent anti-diabetic hormone. 
Findings of effects that DPP IV/CD26 inhibitors exert in preventing 
cleavage of GLP-1, hence increasing active GLP-1 in the circulation, led 
to further studies in the area of DPP IV/CD26 inhibitors development 
[25,26]. Today, numerous DPP IV/CD26 inhibitors are available and 
used in clinical practice, most common of them enlisted in Table 2. 
Scientific research in the field of DPP IV/CD26 inhibitors has 
shown that administration of sitagliptin in diabetic mice decreases 
blood glucose levels and increases the number of beta cells in pancreatic 
islets of mice and pigs. Due to the increased number of beta cells, the 
insulin concentration increased in pancreatic islets [27]. Likewise, 
sitagliptin showed increased proliferation of endothelial cells around 
and inside of the grafts. The localization of cells that form microvessels 
within and around grafts, as well as localization of randomly distributed 
glucagon-positive cells around beta cells was found. Those findings 
suggested increased vascularization as a result of the activation of 
VEGF-A/VEGF-B signal pathway triggered by sitagliptin. Likewise, 
DPP IV/CD26 inhibition improved functional blood flow in grafts 
as a result of inhibitor acting. It is shown that sitagliptin improves 
VEGF secretion in transplanted porcine islets, which contributes to 
cell proliferation and angiogenesis by increasing VEGFR-2 expression 
[28]. DPP IV/CD26 inhibition with linagliptin also showed decreased 
blood glucose levels and accelerated skin re-epithelization in diabetic 
mice since levels of active GLP-1 in wound lysates increased. A reduced 
number of neutrophils and macrophages in linagliptin-treated mice 
were noted [29]. DPP IV/CD26 inhibitors also show pleiotropic effects 
by directly changing cytokine and growth factors expression, increasing 
plasma levels of SDF-1α and numbers of endothelial progenitor cells in 
circulation, which contributes to wound healing [30]. In clinical studies, 
DPP IV/CD26 inhibitor vildagliptin showed accelerated healing of 
chronic diabetic ulcers, with significantly faster rate of wound closure 
compared to the control group, most probably as a result of an increase 
in VEGF and HIF-1α, an important transcriptor factor with crucial role 
in neovascularization [7].
Role of DPP IV/CD26 in Wound Healing in Diabetes
The process of wound healing is a dynamic and complex course of 
action with the aim of regenerating damaged cellular structures and 
tissue layers that involves numerous cells such as endothelial cells, 
fibrocytes, kerationcytes and inflammatory cells. Wound healing is 
divided into several predictable phases: blood clotting (hemostasis), 
inflammation, tissue growth (proliferation), and tissue remodeling 
(maturation). Coagulation occurs one hour after the injury and is 
characterized by vasoconstriction and clot formation. Platelets come to 
the site of damaged blood vessels, initiate the clot formation and excrete 
various cytokines that attract inflammatory cells, growth factors and 
anti-inflammatory factors [31]. Growth factors in the inflammatory 
phase initiate angiogenesis and granulation by excreting growth 
factors such as TGF-β, IGF-1, MIP-1, MCP-2, TNF-α that trigger cell 
movement into the wound and play an important role in extracellular 
matrix formation. Growth factors VEGF and iNOS promote angiogenic 
activity [32]. The inflammatory phase follows the phase of proliferation 
characterized by tissue granulation and angiogenesis. Inflammatory 
cells such as neutrophils and macrophages help in wound debridement. 
Chemotactic factors attract monocytes to the wound where they 
differentiate into macrophages that remove bacteria and nonviable cells 
by phagocytosis. In the migration-proliferation phase, angiogenesis, 
contraction, and proliferation of keratinocytes occur. Fibroblasts 
proliferate inside the wound and make up the extracellular matrix, 
after which matrix metalloproteinases degrade synthesized collagen 
and form a scar. After collagen synthesis, the injured skin returns to its 
normal state. Due to angiogenesis, the supply of oxygen and nutrients 
again contribute to tissue functionality [33]. 
In diabetes, the process of wound healing is impaired due to 
numerous external and internal factors [34]. Chronic wounds, such 
as diabetic ulcers, show pathophysiological abnormalities that lead to 
impaired healing where the progression of tissue regeneration is not 
synchronized. Intrinsic factors such as neuropathy, vascular problems 
and other complications due to hyperglycemia cause impairment 
of wound healing in diabetic ulcers [35]. Extrinsic factors include 
repeated trauma or mechanical stress that lead to wound infection, the 
formation of callus and persistent ulcer formation. Exposure to high 
glucose concentration decreases proliferation and differentiation of 
keratinocytes. In diabetes, chemotaxis and phagocytosis are decreased 
in the early phase of wound healing, and the appearance of cytokine 
and growth factors in the wound is altered. Excessive deposition of 
collagens and fibronectin has also been reported in diabetic wounds 
[36,37]. 
Previous research has shown a significant role of DPP IV/CD26 
in physiological and pathological processes. Important physiological 
functions of DPP IV/CD26 come with interactions with other proteins, 
such as ADA, substance P, VEGF, IP-10, glucagon and NPY [38]. DPP 
IV/CD26 plays an important role in wound healing at several levels: 
via its involvement in degradation of extracellular matrix (ECM), in 
cell adhesion and migration, and angiogenesis. DPP IV/CD26 causes 
degradation of ECM by binding to adenosine deaminase which leads 
to an increase of plasmin levels and the degradation of collagen, 
fibronectin, and laminin by activation of matrix metalloproteases 
Brand Name Active Ingredient(s)
Januvia Sitagliptin
Janumet Sitagliptin and Metformin
Janumet XR Sitagliptin and Metformin extended release
Onglyza Saxagliptin
Kombiglyze XR Saxagliptin and Metformin extended release
Tradjenta Linagliptin
Glyxambi Linagliptin and Empagliflozin
Jentadueto Linagliptin and Metformin
Nesina Alogliptin
Kazano Alogliptin and Metformin
Oseni Alogliptin and Pioglitazone
Table 2: List of FDA-approved DPP IV/CD26 inhibitors in 2015 (FDA Drug 
Safety Communication available online at https://www.fda.gov/downloads/Drugs/
DrugSafety/UCM460038.pdf).
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[39]. Previous studies have shown that DPP IV/CD26 stimulates the 
proliferation of T lymphocytes as well as chemokine secretion which is 
important for migration of inflammatory cells during the inflammatory 
phase. Extended duration of the inflammatory phase, in process of 
wound healing, can lead to chronic wounds and permanent tissue 
damage [31].
In addition, by acting on its substrate SDF-1α, DPP IV/CD26 
decreases its chemotactic activity and consequently, SDF-1α loses its 
lymphocyte and monocyte chemotacticity and signaling properties 
for attracting endothelial progenitor cells at the inflammatory site. 
Furthermore, the enzymatic activity of DPP IV/CD26 on SDF-1α 
decreases its angiogenic properties. Likewise, DPP IV/CD26 acts 
proteolytically on its substrate NPY and terminates the action of NPY 
at its Y1 receptor subtype. Y1 is a receptor important for wound healing 
since it promotes vasoconstriction and proliferation of cells. Cleavage 
of NPY leads to the modulation of the regulation of vascular smooth 
muscle contraction and angiogenesis [40]. Its proteolytic activity on 
chemokines also affects cell migration and cell apoptosis. GLP-1 is a 
DPP IV/CD26 substrate which, under hypoxic conditions, promotes 
upregulation of HIF-1α, a regulator of expression of VEGF. VEGF 
stimulates angiogenesis and neovascularization, influences closing 
of the wounds, formation of granulation tissue and epidermal repair. 
Low VEGF activity in diabetic patient’s leads to insufficient wound 
vascularization and delay in the repair process [19]. On the other side, a 
DPP IV/CD26 substrate, the chemokine IP-10, appears in the first phase 
of wound healing, homeostasis/coagulation phase and plays a role in 
the recruitment of activated CD4, CD8 and NK cells in the liver. DPP 
IV/CD26 mediates cleaving of IP-10, producing an antagonist form of 
the chemokine thus causing failure of vessel regression and tendency 
to ulceration and dehiscence. DPP IV/CD26 reduces the chemotactic 
ability of IP-10 and leaves the ability of IP-10 to inhibit angiogenesis [41]. 
From the aforementioned role of DPP IV/CD26 in wound healing, 
we can assume that DPP IV/CD26 plays a significant role by regulating 
the biological activity of its substrates such as cytokines and chemokines, 
and by its co-stimulatory actions on immune cells. Previous research has 
proven that DPP IV/CD26 impacts wound healing, as CD26 deficient 
mice showed better wound closure and scab formations compared 
to wild-type mice. Inhibition of DPP IV/CD26 activity during skin 
regeneration improves the clearance of elevated blood glucose levels 
and reduces high DPP IV/CD26 activity in chronic wound tissue of 
diabetic mice [29]. Animal studies in diabetic mice revealed increased 
DPP IV/CD26 levels in the presence of enhanced wound inflammatory 
conditions [42]. Our research group also demonstrated an important 
role of DPP IV/CD26 in the process of wound healing [43]. We showed 
an increase in epithelium thickness, corium connective tissue, and 
extracellular matrix was demonstrated in CD26 deficient mice during 
wound healing. Furthermore, an important role of DPP IV/CD26 has 
been shown in neovascularization: CD26 deficient mice show a prompt 
response in neovascularization and a higher number of capillaries on the 
second day of wound healing compared to wild-type mice. The impact 
of DPP IV/CD26 is also visible in cell proliferation, where the number 
of proliferating cells is higher in all analyzed days in CD26 deficient 
mice comparing to wild-type mice. The influence of DPP IV/CD26 on 
VEGF expression is related to the capability of DPP IV/CD26 to cleave 
GLP-1 which under hypoxic conditions promotes the upregulation of 
HIF-1α, a regulator of expression of VEGF. It was shown that on all days 
post wounding, VEGF expression was higher in CD26 deficient mice, 
as well as HIF-1α expression, which was twice higher in CD26 deficient 
mice than in wild-type mice. An impact of DPP IV/CD26 on immune 
cells at the site of tissue regeneration has also been noticed during 
the wound healing process. Moreover, DPP IV/CD26 influences the 
concentration of IP-10, an angiostatic molecule substrate of DPP IV/
CD26 whose values are significantly higher in CD26 deficient animals 
during wound healing. Clinical studies as well showed that DPP IV/
CD26 inhibitors may contribute to the healing of wounds. Vildagliptin, 
a DPP IV/CD26 inhibitor used in clinical practice induced increased 
levels of GLP-1, nitrotyrosine, proteasome 20S activity, HIF-1α, VEGF 
and capillary density, as well as improved wound healing in chronic 
diabetic ulcers [7] which opens new possibilities to pharmaceutical 
treatment of wound healing in diabetic patients.
Conclusion
Understanding the events of tissue regeneration provides a 
framework for developing new therapeutic agents with a positive 
impact on wound healing processes in diabetic patients. The inhibition 
of DPP IV/CD26, in addition to its established glycaemic control, 
shows positive impacts in the local wound healing in diabetic ulcers. 
Given the importance of DPP IV/CD26 in the regulation of glucose 
homeostasis as well as in the processes of tissue regeneration and 
reparation, this field indeed needs further scientific efforts in order to 
elucidate potential sites of pharmaceutical action aiming to manage 
devastating consequences of chronic diabetic ulcers.
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